Hypersensitivity Reactions: Practice Recommendations for Paclitaxel Administration.

Area of Science:

• Oncology Nursing
• Clinical Pharmacy
• Patient Safety

Background:

• Paclitaxel is a critical intravenous oncology medication frequently associated with hypersensitivity reactions (HSRs).
• Incidence of HSRs ranges from 10% to 40%, typically occurring during the initial infusions.
• Current literature lacks definitive guidance on optimal administration protocols to mitigate HSRs.

Purpose of the Study:

• To address safety concerns and variability in paclitaxel administration practices.
• To improve patient safety by minimizing the incidence and severity of HSRs.
• To establish evidence-based guidelines for paclitaxel administration.

Main Methods:

• A team-based quality improvement project was initiated by an advanced oncology clinical nurse specialist.
• A retrospective chart review was conducted to evaluate outpatient paclitaxel administration practices and documentation.
• Data analysis informed the development and reinstatement of a standardized order set.

Main Results:

• The quality improvement project identified inconsistencies in current paclitaxel administration protocols.
• The study provided data supporting the need for standardized administration procedures.
• Results formed the basis for implementing a revised standard order set.

Conclusions:

• Reinstating a standard order set for paclitaxel administration is crucial for patient safety.
• Titration of paclitaxel during the first and second infusions is recommended to minimize HSRs.
• Standardized protocols enhance the safe delivery of high-alert oncology medications.